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Abstract
A drug candidate suitable for clinical testing is expected to bind selectively to the receptor site on
the target, to elicit the desired functional response of the target molecule, and to have adequate
bioavailability and biodistribution to elicit the desired responses in animals and humans; it must also
pass formal toxicity evaluation in animals. The path from lead to clinical drug candidate represents
the most idiosyncratic segment of drug discovery and development. Each program is unique and
setbacks are common, making it difficult to predict accurately the duration or costs of this segment.
Because of incidents of unpredicted human toxicity seen in recent years, the regulatory agencies
and public demands for safety of new drug candidates have become very strict, and safety issues
are dominant when identifying a clinical drug candidate.
Introduction
Modern drug discovery and development efforts typically
emerge from basic research and then gradually move on
to specific sequential tasks, which – if successful – culmi-
nate in a new drug for the treatment of a human disease.
The overall pathway is structured by well-delineated mile-
stones, which include selection of the drug target, identi-
fication of a lead compound, its modification to a
compound suitable for toxicity testing in animals, and
selection as drug candidate for clinical testing. Although
the road is well mapped out, it is by no means easy or
guaranteed to end in success. Even before the onset of
human studies, a drug candidate suitable for clinical test-
ing is expected to satisfy specific and demanding criteria.
It must bind selectively to the receptor site on the target
and elicit the desired functional response from the target
molecule. It must have sufficient bioavailability and dis-
tribution within the body to reach the receptor site, and it
must elicit the desired responses in vivo, in animal models
of the human disease. Most importantly, a drug candidate
suitable for testing in humans must pass a formal toxicity
evaluation in animals, to demonstrate that humans par-
ticipating in the clinical studies are exposed to minimal
risks only.
For many decades, knowledge and experience about drug
discovery and preclinical drug development have been
safeguarded by the pharmaceutical companies, and there
was little outside interest. More recently, with the growth
of the biotechnology industry and its open interface to
academic research, drug discovery and development have
become widely recognized as important, unique, and
challenging activities.
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From lead molecule to a drug candidate suitable 
for testing in formal animal toxicity studies
The broad availability of chemical compound libraries
and automatic screening technologies has made it rela-
tively easy to identify initial lead candidates for new drug
targets [1]. High quality leads are compounds that already
satisfy some of the criteria for a future drug candidate.
Chemists at Pfizer developed the so-called rule of five for
leads and drug candidates [2]. The rule stipulates that
molecules must have a molecular weight less than 500 g/
mol, a partition coefficient (logP – a measure of hydro-
phobicity) less than 5, no more than five hydrogen bond
donors, and no more than 10 hydrogen bond acceptors.
Modern sample collections contain many molecules that
violate the rule of five. Keeping the molecular weight
under 500 has become particularly difficult because broad
synthetic efforts naturally tend to increase the size of the
chemicals. However, most successful drugs have molecu-
lar weights below 500 and logP values below 5, and failed
compounds tend to fall outside this range [3]. In addition
to satisfying the rule of five, high quality leads will have
appropriate selectivity for the intended target, rather than
giving positive signals in different screening assays. High
quality leads will be attractive from the point of view of
synthetic chemistry and offer diverse routes for multiple
chemical modifications. Optimally, there will already be
useful information on pharmacokinetic properties, show-
ing that they are within a reasonable range of bioavailabil-
ity and half-life. From the neuroscience perspective, it is
particularly useful to have information on blood-brain
barrier penetration.
Selection of a lead compound is followed by the initiation
of a synthetic medicinal chemistry program. Table 1 lists
the properties expected from a molecule taken into the
expensive and time-consuming formal animal toxicity
studies, which precede testing in humans. The criteria are
vague by necessity, because they are determined by the
intended route of administration and human disease tar-
geted. In broad strokes, a molecule must satisfy basic
needs of future manufacturing and storage. It has to pro-
duce the desired pharmacologic effects on the target and
in animal models of the disease, with a route of adminis-
tration and frequency of dosing commensurate with prac-
tical use in humans. It cannot produce any obvious signs
of toxicity that preclude use in humans. Each medicinal
chemistry program is unique, because it must focus on the
deficiencies of the lead molecules.
Each individual deficiency in efficacy, specificity, pharma-
cokinetic properties, and toxic potential must be
addressed by defining the structure-activity relationship
for the binding site that mediates an effect, and by synthe-
sizing analogs that avoid the undesired binding sites. Each
step taken and each deficiency resolved will affect other
properties, making it impossible to address them in sim-
ple sequential order. Nevertheless, in a medicinal chemis-
try program, the selectivities of the leads are typically
addressed first. Leads are evaluated in a broad counter-
screening program, in which they are tested for affinity to
most of the known drug receptor sites. These tests typi-
cally identify a small number of undesired binding affini-
ties that must be worked out of the compound through
chemical modifications. Counter-screen assays for the
Table 1: Desired properties for drug candidate taken for evaluation in formal animal toxicity studies.
Properties Details
Chemical properties Stable molecule
Nonproblematic synthesis with potential for scale-up
Pharmacological properties Selective high-affinity binding to target binding site
Selective and potent functional effect on target receptor molecule in vitro
Effectiveness in animal model of targeted human indication
Pharmacokinetics Adequate bioavailability for selected route of administration
Adequate half-life and biodistribution for intended use
Safety and toxicity Satisfactory profile for inhibition and induction of cytochrome P450 enzymes
Absence of obvious cardiac toxicity (hERG binding)
Absence of obvious toxicity in animal studiesBMC Neuroscience 2008, 9(Suppl 3):S7 http://www.biomedcentral.com/1471-2202/9/S3/S7
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undesired affinities in a lead compound often remain an
issue for the subsequent series of chemical derivatives,
and they become part of the routine assays used in sup-
port of furthering the medicinal chemistry program.
Achieving adequate affinity to the receptor site is the next
main goal of the medicinal chemistry program. To reach
sufficient selectivity and potency in vivo, it is necessary to
find compounds with binding affinities in the low
nanomolar or even picomolar range. Binding assays are
relatively simple and highly suitable for determining the
affinity. Compounds with sufficiently high affinity move
on to further assays that determine the functional effects
on the target molecule, in order to distinguish agonistic
from antagonistic responses. Binding and functional
assays define the in vitro segment of the medicinal chem-
istry selection process. Compounds with sufficient bind-
ing affinity, selectivity, and functional efficacy are taken
forward into further in vivo selection processes.
The in vivo assays serve to select compounds with satisfac-
tory pharmacokinetic properties to reach the receptor site
and to elicit the desired effect in animal models of the dis-
ease. There is a high degree of variability among drug dis-
covery projects in the specific way in which this is
handled. In the simplest possible case, a single animal
model can satisfy all of these needs. The biologic efficacy
of a compound in a predictive animal model after oral
administration implies sufficient bioavailability and
receptor occupancy, as well as appropriate effects on the
receptor. For most drug discovery projects, however, these
different steps are evaluated with individual assays. Stand-
ard pharmacokinetic methods are used to measure bioa-
vailability and to select compounds with satisfactory
properties. In vivo receptor occupancy assays determine
adequate binding to the receptor. Finally, a functional
model of the disease serves to measure the appropriate
biologic response. The level of difficulty and capacity of
the available in vivo models drive these decisions. Very
often, animal models of specific diseases are complex and
require treatment durations of several months. General
comments on this topic would inappropriately blur and
trivialize the large differences among drug discovery pro-
grams.
It is advantageous to incorporate early in medicinal chem-
istry programs assays that address specific safety concerns.
Cardiovascular effects for example, even when minor, rep-
resent major problems for a drug candidate, because they
could lead to sudden death in patients. Of particular con-
cern are drugs that increase the QT interval in the
sequence of cardiac contractions, because they predict an
increased risk for heart attack [4]. The IKr ion channel is
the key determinant of the QT interval, and unfortunately
this channel has a binding site with significant structural
overlap with many G-protein-coupled receptor drug-
binding sites. Thus, IKr receptor site binding assays – in
particular the human gene product that forms the chan-
nel, namely hERG (human ether-à-go-go-related gene) –
are often incorporated into routine in vitro counter-screen-
ing batteries. In a similar way, inhibition or induction of
cytochrome P450 enzymes, which are responsible for the
majority of metabolic transformations of drugs, are often
monitored early with in vitro systems.
In every program it is possible to detect significant toxicity
issues by careful observations of animals used in efficacy
studies. Major behavioral changes in motor activity, excre-
tory functions, and body colors indicate potentially prob-
lematic effects. Inspection of organs after necropsy often
divulges hints about toxic effects in the absence of exten-
sive histopathology studies. Such casual observations, as
well as exploratory toxicity studies, can play a major role
in a drug discovery project, because they help to avoid set-
backs after the time consuming formal animal toxicity
studies.
Drug discovery projects evolve with time in distinct pat-
terns. During the early stages the biologic assays are
adjusted and optimized. Redundant steps are omitted.
Mature drug discovery programs have a well-established
critical path of in vitro and in vivo biologic assays by which
chemicals are selected. Minimizing and optimizing the
steps of the critical path is one of the keys to success in
drug discovery. An optimized critical path allows the drug
discovery researcher to select the best compound at each
step without redundancies. The critical path will change if
new issues are encountered that need to be resolved. The
selection process of an optimized medicinal chemistry
program and critical path has similarity to the Darwinian
selection process of biologic evolution. However, chemi-
cals are not randomly generated as are the mutations in
biology, but rather they are designed based on rational
considerations. The path from target selection to identify-
ing a drug candidate is long and complicated. In rare
cases, a few hundred molecules are necessary to achieve
success, but it may be necessary to synthesize several thou-
sands of molecules before an acceptable drug candidate
emerges. Several years and large groups of chemists and
biologists are often necessary to achieve this goal.
The basic criteria listed in Table 1 are applicable for small
organic molecules as well as for biologic drug candidates.
The success of natalizumab in multiple sclerosis [5] dem-
onstrates that antibodies can be useful for the treatment of
neurodegenerative diseases. High specificity and long
half-life are key advantages of antibodies. In recent years,
small inhibitory RNAs have emerged as new and highly
attractive biologic drug candidates. The sequential steps
by which molecular biologic methods are used to improveBMC Neuroscience 2008, 9(Suppl 3):S7 http://www.biomedcentral.com/1471-2202/9/S3/S7
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the antibodies and small inhibitory RNAs are analogous
to those of a medicinal chemistry program. The critical
path of in vitro and in vivo assays is closely similar; selec-
tivity, potency, and efficacy must be established in the
selection of the final drug candidate.
Requirements for drug candidate suitable for 
human studies
In all countries, clinical studies with experimental drugs
require the approval of regulatory agencies, who exercise
substantial and dominant control over drug testing
requirements and ultimate approval. In the USA regula-
tory oversight is provided by the Food and Drug Adminis-
tration (FDA), whose activities are governed by law. The
FDA requires filing of a Notice of Claimed Investigational
Exemption for a New Drug (IND) for approval to proceed
to clinical studies with a new drug candidate. The IND
application describes the composition and synthesis of
the drug candidate, and the data from in vitro studies and
animal experimentation, as well as the clinical plans. The
criteria used in the evaluation are explained in various
publicly available guidance documents [6]. The essential
features are listed in Table 2. Approval of an IND makes it
possible to proceed to clinical testing of a drug candidate
and is justifiably considered a very significant milestone
in drug development.
Minimizing the risk to participants in clinical studies
requires that drug candidate material be manufactured,
stored, and delivered according to highest specifications.
Accordingly, these activities, which are generally referred
to as Chemistry, Manufacturing, and Control (CMC), are
intensely regulated. Adherence to standardized and regu-
larly updated Good Manufacturing Practices is manda-
tory. A detailed description of these requirements would
be beyond the scope of this short review and can be found
in various regulatory guidance documents [6]. In essence,
they ensure that the drug candidate is being produced in
reliable and reproducible ways, where eventual impurities
are characterized and shown not to be toxic, and that the
material can be stored and delivered without degradation.
Academic units and small biotechnology companies typi-
cally outsource CMC activities to specialized companies,
whereas the large pharmaceutical companies have intra-
mural units that specialize in these tasks.
To plan human studies and to minimize risk, it is neces-
sary to make plausible predictions about the fate of the
drug candidate in the human body after administration.
Relevant predictive information, typically referred to as
Administration, Distribution, Metabolism, and Excretion
data, must obtained in animal studies before administra-
tion to humans. Initial information on the pharmacoki-
netic behavior of lead compounds and derivatives is
typically obtained earlier in the medicinal chemistry pro-
Table 2: Information needed to support request for clinical testing of a drug candidate (IND filing to FDA).
Information Details
Chemistry, Manufacturing and Control (CMC) Compound with acceptable stability and formulation
Controlled production under cGMP (current Good Manufacturing Processes)
Absorption, distribution, metabolism and excretion (ADME) Route of administration, half-life
Metabolic pathways
Potential drug-drug interactions (including effects on cytochrome P450 enzymes)
Toxicology Systemic and organ toxicity: gross and microscopic changes; two animal species, 
covering time periods of intended human exposure
Estimated safety window between efficacious dose and 'no observed adverse effect 
level' (NOAEL)
Initial data on potential genotoxicity and cardiotoxicity
Mechanism of action and pharmacology Effects on receptor in vitro
Efficacy in animal models in vivo
Clinical development plans Detailed protocol of initial studies
FDA, Food and Drug Administration; IND, Notice of Claimed Investigational Exemption for a New Drug.BMC Neuroscience 2008, 9(Suppl 3):S7 http://www.biomedcentral.com/1471-2202/9/S3/S7
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gram. For submission of the IND, these exploratory stud-
ies must be supplemented by results from more formal
studies. Pharmacokinetic parameters – including bioavail-
ability after oral or other systemic administration, plasma
half-life, volume of distribution, clearance, and exposure
– are determined in two or three animal species. Using
established interspecies conversation factors, these data
are than used to predict the human parameters.
Before use of a drug candidate in humans, it is necessary
to characterize its metabolic transformations in the body.
The vast majority of small organic molecules undergo
metabolic transformation through hydroxylation and
dealkylation, as well as conjugation reactions that cova-
lently link the drug to naturally occurring hydrophilic
compounds. Metabolic transformation of drugs some-
times generates unexpected toxic products. In every drug
discovery project it is thus necessary to characterize the
major metabolites and to assess their potential toxicity.
Metabolic transformation determines the potential of a
drug candidate to interfere with the function of another
drug. Because drug-drug interactions often determine the
success of a drug in medical practice, it is necessary to
understand in detail their effects on metabolic enzymes in
addition to the study of their own transformation. Meta-
bolic transformations vary from molecule to molecule
and can vary from species to species, often rendering their
study a very complex and difficult task.
Formal toxicity studies in animals are the most important
component of the characterization of a new drug candi-
date. They have to be carried out following the procedures
of Good Laboratory Practice. The time period of adminis-
tration to animals must exceed the intended treatment
duration in humans. Plasma levels must reach sufficiently
high levels to yield adequate high exposure to the tested
drug candidate. Typically, during the course of the safety
studies, toxic effects become apparent at the higher dose
levels. These easily observable high-dose effects then
guide the investigators in the search for less obviously
toxic effects at lower doses. Besides behavioral observa-
tions, body fluid composition is analyzed for abnormali-
ties and, at the end of the study, the organs of the test
animals are weighed and the tissues processed for histo-
logical analysis. The toxicity studies provide an initial def-
inition of the therapeutic window for a drug candidate. A
20-fold or higher difference is typically desired between
clinically effective plasma levels in humans and those pro-
ducing toxicity in animals. In addition, before clinical
studies, all drug candidates must be evaluated in the
standard in vitro tests predicting genotoxicity. Toxicity test-
ing is the most unpredictable and most frustrating step in
drug discovery and development. Most pharmaceutical
companies share the experience that about three out of
five small molecule drug candidates fail in animal toxicity
testing for unpredictable and unknown reasons. Failure of
a drug candidate in toxicity testing may set a program back
by several months if not years, because new analogs with-
out toxicity must be identified. To minimize this risk,
experienced pharmaceutical companies typically generate
several backup compounds in each medicinal chemistry
program, with the hope that one among them will be
devoid of toxicity.
The high attrition rate in safety testing observed with
small organic compounds emphasizes the main advan-
tage of biologic drugs. Biologics are less likely to exhibit
unpredictable off-target activities than small organic mol-
ecules of xenobiotic origin. In addition, peptides, pro-
teins, and RNAs tend to have simpler and more
predictable metabolic pathways and pharmacokinetic
properties. Consequently, the failure rate of biologics in
animal toxicity studies tends to be lower than that of
small organic molecules. These advantages have been
widely recognized and drive the multiple attempts to gen-
erate biologic rather than small organic molecule drug
candidates.
Broad information on mechanism of action and pharma-
cology is typically available for a clinical drug candidate.
Information on in vivo efficacy maintains the enthusiasm
for the program through the years of ongoing clinical
studies, before clinical data become available. However,
efficacy data are less critical than safety and toxicity data
for the actual IND submission. A simple set of animal
studies, sometimes even a plausible rationale, are suffi-
cient to support the pharmacology part of an IND submis-
sion. Similarly, the clinical plans provided must
emphasize safety. An overall clinical investigational plan
must be provided, but the focus should on the detailed
design of the early human safety studies. Patient safety is
the absolute and primary concern in drug discovery and
development, and the medical oath of not doing harm
applies just as rigorously for participating drug discovery
researchers.
Conclusion
The path from lead to clinical drug candidate is not linear,
even though it is often depicted as a sequence of modular
activities and milestones. Figure 1 is an attempt to reflect
the complex, modular interactions encountered in drug
discovery projects. Each program is unique and tends to
be idiosyncratic, defying generalization. Setbacks and fail-
ures occur frequently. Accordingly, the segment between
lead and clinical drug candidate is often referred to as the
'zone of chaos', 'problem solving period', or 'valley of
death' within the drug discovery and development path-
way. To the great frustration of planners in funding agen-
cies, universities, and companies, it is extremely difficult
to predict accurately the duration or costs of this segment.BMC Neuroscience 2008, 9(Suppl 3):S7 http://www.biomedcentral.com/1471-2202/9/S3/S7
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On the positive side, it provides one of the most challeng-
ing and interesting of scientific activities [7].
Drug discovery programs are initiated and driven by the
belief that an efficacious new drug can be identified and
made available to suffering human patients. The positive
signals and data for efficacy drive the program forward. In
contrast, in the phase of selecting and characterizing a
clinical drug candidate, the focus must be on human
safety. Because of several incidents of unpredicted toxicity
observed in human studies in recent years, the regulatory
agencies and public demands for safety are stricter than
ever before. Safety issues and concerns require the highest
attention when identifying a clinical drug candidate.
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